The novel agent VMT01 is designed to target and deliver 212Pb to MC1R-expressing tumors like metastatic melanoma.
2024
Breaking the trend: Sweden sees skin cancer decline in under-50s for first time
The risk of skin cancer, malignant melanoma, now appears to be decreasing in Sweden—at least in those under 50, according to a new study.
Experts Report Moderate Patient Adherence to Melanoma Screening and Surveillance Program
Researchers tailored screening and surveillance schedules to individual risk of patients.
EU and UK approve Microbiome Medicines for advanced melanoma and ulcerative colitis
Microbiotica has received the green light from EU and UK regulatory authorities to start phase 1b studies for its microbiome medicines in advanced melanoma and ulcerative colitis.